Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Thermofisher Scientific and Janssen Pharmaceuticals - Riding the new waves of success: Latest strategies in the screening and management of NSCLC patients with EGFR exon 20 insertion mutations

Closing remarks

Date

02 Dec 2022

Session

Thermofisher Scientific and Janssen Pharmaceuticals - Riding the new waves of success: Latest strategies in the screening and management of NSCLC patients with EGFR exon 20 insertion mutations

Topics

Pathology/Molecular Biology;  Molecular Oncology

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Ross Soo

Authors

R.A. Soo

Author affiliations

  • Haematology-oncology Department, NCIS - National University Cancer Institute Singapore, 119074 - Singapore/SG

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.